Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 8 | 2024 | 697 | 1.210 |
Why?
|
| Obesity | 10 | 2021 | 1235 | 0.890 |
Why?
|
| Leptin | 4 | 2024 | 85 | 0.820 |
Why?
|
| Bone and Bones | 2 | 2024 | 139 | 0.620 |
Why?
|
| Hyperglycemia | 1 | 2020 | 104 | 0.620 |
Why?
|
| Glucocorticoids | 2 | 2020 | 188 | 0.610 |
Why?
|
| Primary Prevention | 1 | 2017 | 136 | 0.500 |
Why?
|
| Juglans | 3 | 2021 | 11 | 0.470 |
Why?
|
| Health Status | 1 | 2017 | 436 | 0.450 |
Why?
|
| Follistatin | 3 | 2021 | 44 | 0.450 |
Why?
|
| Anti-Obesity Agents | 3 | 2019 | 14 | 0.440 |
Why?
|
| Risk Assessment | 2 | 2024 | 2079 | 0.430 |
Why?
|
| Nephrosis | 1 | 2013 | 3 | 0.420 |
Why?
|
| Hypoparathyroidism | 1 | 2013 | 7 | 0.420 |
Why?
|
| Diabetes Complications | 1 | 2014 | 106 | 0.420 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 701 | 0.410 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 48 | 0.400 |
Why?
|
| Hospitalization | 1 | 2020 | 1364 | 0.390 |
Why?
|
| Energy Metabolism | 4 | 2024 | 379 | 0.350 |
Why?
|
| Neurosecretory Systems | 2 | 2024 | 24 | 0.340 |
Why?
|
| Weight Loss | 3 | 2019 | 274 | 0.290 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 4 | 2 | 2018 | 5 | 0.290 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 2 | 2018 | 7 | 0.290 |
Why?
|
| Blood Glucose | 3 | 2020 | 484 | 0.280 |
Why?
|
| Benzazepines | 2 | 2019 | 21 | 0.280 |
Why?
|
| Activins | 2 | 2018 | 54 | 0.270 |
Why?
|
| Fibronectins | 2 | 2017 | 43 | 0.270 |
Why?
|
| Insulin Resistance | 3 | 2021 | 412 | 0.270 |
Why?
|
| Heart Failure | 2 | 2024 | 913 | 0.260 |
Why?
|
| Metabolic Diseases | 2 | 2017 | 58 | 0.250 |
Why?
|
| Humans | 26 | 2024 | 63449 | 0.230 |
Why?
|
| Double-Blind Method | 7 | 2021 | 739 | 0.230 |
Why?
|
| Androgen Antagonists | 1 | 2024 | 25 | 0.230 |
Why?
|
| Coronary Artery Disease | 2 | 2018 | 313 | 0.210 |
Why?
|
| Middle Aged | 15 | 2024 | 17613 | 0.210 |
Why?
|
| Autoantibodies | 2 | 2016 | 182 | 0.200 |
Why?
|
| Food Preferences | 2 | 2021 | 51 | 0.200 |
Why?
|
| Stroke Volume | 1 | 2024 | 329 | 0.200 |
Why?
|
| Risk Factors | 4 | 2024 | 5354 | 0.190 |
Why?
|
| Female | 18 | 2024 | 32881 | 0.190 |
Why?
|
| Homeostasis | 1 | 2024 | 368 | 0.190 |
Why?
|
| Male | 17 | 2024 | 29891 | 0.180 |
Why?
|
| Fasting | 2 | 2019 | 51 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 2458 | 0.180 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2021 | 6 | 0.180 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2021 | 13 | 0.170 |
Why?
|
| Myocardial Infarction | 2 | 2018 | 916 | 0.170 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 418 | 0.170 |
Why?
|
| Thyroid Neoplasms | 1 | 2021 | 74 | 0.170 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 220 | 0.160 |
Why?
|
| Body Weight | 2 | 2019 | 378 | 0.160 |
Why?
|
| Gastrointestinal Hormones | 1 | 2019 | 10 | 0.160 |
Why?
|
| Liraglutide | 1 | 2019 | 4 | 0.160 |
Why?
|
| Metabolic Syndrome | 2 | 2017 | 142 | 0.150 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 61 | 0.150 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 121 | 0.150 |
Why?
|
| Eating | 1 | 2019 | 138 | 0.150 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2018 | 85 | 0.140 |
Why?
|
| Follistatin-Related Proteins | 1 | 2018 | 22 | 0.140 |
Why?
|
| Reproduction | 1 | 2018 | 92 | 0.140 |
Why?
|
| Appetite Regulation | 1 | 2017 | 8 | 0.140 |
Why?
|
| Nuts | 1 | 2017 | 6 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2024 | 6658 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 507 | 0.140 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2017 | 9 | 0.140 |
Why?
|
| Prognosis | 3 | 2021 | 1748 | 0.140 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2016 | 165 | 0.130 |
Why?
|
| Functional Food | 1 | 2017 | 37 | 0.130 |
Why?
|
| Aged | 7 | 2024 | 14447 | 0.130 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2016 | 12 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2017 | 162 | 0.130 |
Why?
|
| Receptor, Insulin | 1 | 2016 | 50 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 152 | 0.130 |
Why?
|
| White Matter | 1 | 2017 | 123 | 0.120 |
Why?
|
| Incidence | 1 | 2020 | 1377 | 0.120 |
Why?
|
| Glycoproteins | 1 | 2017 | 187 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2017 | 262 | 0.120 |
Why?
|
| Diet | 1 | 2019 | 527 | 0.120 |
Why?
|
| Case-Control Studies | 4 | 2021 | 1119 | 0.120 |
Why?
|
| Cross-Over Studies | 3 | 2021 | 161 | 0.110 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2014 | 20 | 0.110 |
Why?
|
| Comorbidity | 1 | 2017 | 1120 | 0.110 |
Why?
|
| WT1 Proteins | 1 | 2013 | 6 | 0.110 |
Why?
|
| GATA3 Transcription Factor | 1 | 2013 | 17 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2016 | 268 | 0.100 |
Why?
|
| Parathyroid Hormone | 1 | 2013 | 43 | 0.100 |
Why?
|
| Prevalence | 1 | 2017 | 1380 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 332 | 0.100 |
Why?
|
| Cues | 3 | 2019 | 75 | 0.100 |
Why?
|
| Animals | 4 | 2024 | 20659 | 0.090 |
Why?
|
| Felty Syndrome | 1 | 2011 | 2 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 835 | 0.090 |
Why?
|
| Neurons | 1 | 2017 | 922 | 0.090 |
Why?
|
| Brain | 2 | 2017 | 1552 | 0.090 |
Why?
|
| Young Adult | 3 | 2018 | 4694 | 0.090 |
Why?
|
| Postprandial Period | 2 | 2019 | 19 | 0.080 |
Why?
|
| Histones | 1 | 2011 | 481 | 0.070 |
Why?
|
| United States | 1 | 2020 | 7846 | 0.070 |
Why?
|
| Energy Intake | 2 | 2019 | 171 | 0.070 |
Why?
|
| Cognition | 2 | 2019 | 484 | 0.060 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2018 | 209 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 978 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2017 | 867 | 0.050 |
Why?
|
| Adult | 5 | 2019 | 16824 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 2576 | 0.040 |
Why?
|
| Glicentin | 1 | 2019 | 1 | 0.040 |
Why?
|
| Oxyntomodulin | 1 | 2019 | 2 | 0.040 |
Why?
|
| Peptide YY | 1 | 2019 | 3 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 33 | 0.040 |
Why?
|
| Reward | 1 | 2019 | 87 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2019 | 84 | 0.040 |
Why?
|
| Breakfast | 1 | 2017 | 1 | 0.030 |
Why?
|
| Satiety Response | 1 | 2017 | 5 | 0.030 |
Why?
|
| Creatine | 1 | 2017 | 24 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 2172 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2017 | 97 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 74 | 0.030 |
Why?
|
| Time Factors | 1 | 2024 | 3768 | 0.030 |
Why?
|
| Lipids | 1 | 2019 | 315 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2017 | 129 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2016 | 15 | 0.030 |
Why?
|
| Azathioprine | 1 | 2016 | 27 | 0.030 |
Why?
|
| Boston | 1 | 2017 | 253 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 377 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1094 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2016 | 30 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 305 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 148 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2017 | 203 | 0.030 |
Why?
|
| Rituximab | 1 | 2016 | 87 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2016 | 105 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2016 | 205 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 347 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 465 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 978 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 378 | 0.030 |
Why?
|
| Emotions | 1 | 2016 | 223 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1256 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2024 | 5680 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2017 | 382 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 1408 | 0.030 |
Why?
|
| Aging | 1 | 2017 | 745 | 0.020 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2011 | 26 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 540 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2570 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1553 | 0.020 |
Why?
|
| Autoantigens | 1 | 2011 | 137 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 3293 | 0.020 |
Why?
|
| Exercise | 1 | 2017 | 942 | 0.020 |
Why?
|
| Neutrophils | 1 | 2011 | 377 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 337 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 5462 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 6245 | 0.010 |
Why?
|